Over the past decade, drug-eluting stents (DES) have greatly transformed the field of interventional cardiology. Generally, three components are included in a DES system: a metal stent platform, a ...
The current debate in cardiology centers on the use of drug-eluting balloons (DEBs) vs drug-eluting stents (DESs) in de novo lesions. However, to reach this conclusion, it must be shown that the ...
Hosted on MSN
Drug-eluting balloon may be as safe, effective as conventional stents for repeat percutaneous coronary interventions
A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...
A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...
Figure 1. Colorized scanning electron microscope (SEM) image of a biodegradable drug-eluting coating on a coronary stent. Catheter-based interventions have revolutionized the practice of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A bioadaptor implant was linked to fewer CV event rates ...
WASHINGTON--(BUSINESS WIRE)--Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant benefit of the DynamX ...
Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to control group consisting of drug-eluting stent (DES) and balloon angioplasty (BA) ...
Hosted on MSN
Novel sirolimus-eluting balloon appears noninferior to conventional therapies for treatment of in-stent restenosis
Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to a control group consisting of drug-eluting stent (DES) and balloon angioplasty (BA ...
On March 1, Boston Scientific Corp.’s Agent drug-coated balloon (DCB) became the first DCB to gain U.S. FDA approval for treatment of in-stent restenosis in patients with coronary artery disease. With ...
CoSo Health to exclusively distribute Medinol's most advanced coronary DES in the U.S. DENVER and TEL AVIV, Israel, Oct. 24, 2023 /PRNewswire/ -- Medinol today announced United States Food and Drug ...
Dr. Mehran is a co-Principal Investigator of the breakthrough "SELUTION4ISR Trial," with results presented at Transcatheter Cardiovascular Therapeutics 2025. A new drug-eluting balloon can perform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results